Flot.bio x Philip Hemme
by Flot.bio
Latest episode
Red Hot Rare Diseases and Europe’s record funding with Regina…
Red Hot Rare Diseases and Europe’s record funding with Regina…
About this podcast
Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free.
Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.
Episodes
The newest 20 of 63 episodes
- Red Hot Rare Diseases and Europe’s record funding with Regina Hodits, Angelini Ventures | E63 · 31 min · Episode 63Regina Hodits, who I have known for many years, spent 15 years at Wellington Partners before joining Angelini Ventures in 2025. The corporate venture fund now manages close to…
- MedinCell CEO on Long-Acting Drugs & France’s $1B Biotech Club | Christophe Douat | E62 · 57 min · Episode 62Christophe has run MedinCell since 2009, when it was eight people in a converted garage. Today it's one of only three French biotechs to ever cross $1B on Euronext.With one…
- Billionaire wild bets on Consumer Biotech, GLP-1s, and psychedelics | Christian Angermayer | E61 · 1 h 14 min · Episode 61Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of…
- ImCheck ex-CEO on ASCO Oncology Trends, $1.2B Exit and French Biotech | Pierre d’Epenoux | E60 · 47 min · Episode 60After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen in 2025. In a session at the Kadans…
- CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored] · 1 h 1 min · Episode 59Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for $70M this year, a product of years of collaboration and stepwise…
- Ex-CEO of Incyte Hervé Hoppenot on 10x Growth, Biotech Cycles, and Breaking Bureaucracy | E58 · 59 min · Episode 58When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US was choppy. By the time he left in 2025, he had grown their revenue from $300 million to a whopping…
- Christoph Lengauer, Curie.Bio | Biotech Founders, Venture Capital | E57 · 1 h 19 min · Episode 57We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that now manages $1.25B and backs 38 portfolio companies.We discuss Curie.Bio’s track…
- Sander Slootweg, Forbion 🇳🇱 | European Biotech Investment, Venture Capital | E56 · 1 h 6 min · Episode 56Forbion celebrates its 20th anniversary this year, with a whopping €5 billion raised so far. Sander marks the occasion by discussing how Forbion plans to promote life sciences…
- Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored] · 1 h 2 min · Episode 55Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they’re tackling the crisis with vaccines. We…
- António Portela, Bial 🇵🇹 | Parkinson’s, Family-Owned Biotech | E54 · 31 min · Episode 54We dive into Bial’s meteoric journey from a small pharmacy in Porto to Portugal’s biggest biopharma company, all while still being 100% family owned. We cover Bial’s pipeline…
- Claus Crone Fuglsang, Novonesis 🇩🇰 | Biosolutions, Industrial biotech, Synbio | E53 · 1 h 10 min · Episode 53Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low…
- Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug Repurposing, Retail Investors | E52 [Sponsored] · 1 h 24 min · Episode 52At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial…
- Fredrik Tiberg, Camurus 🇸🇪 | Opioid Crisis, Long-Acting Injections | E51 · 1 h 0 min · Episode 51Founded in 1991, Camurus has grown into a $4B biotech with two products in the market, a rich pipeline, and 290 employees.Fredrik explains how Camurus’ long-acting injections —…
- Alessandro Riva, Transgene | Cancer Vaccines, Oncolytic Viruses | E50 · 1 h 5 min · Episode 50Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and…
- Pascal Touchon 🇫🇷 | Cell Therapy, Jeito, Kymriah | E49 · 1 h 14 min · Episode 49Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting. The cell therapy master outlines his central role…
- Werner Lanthaler 🇦🇹 | Biopharma AI, CDMO, Antibody Optimization | E48 · 60 min · Episode 48Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and hard to solve, Werner told Philip in Vienna.We revisit Werner in…
- Thomas Lingelbach, Valneva | Vaccines, Lyme Disease | E47 · 44 min · Episode 47Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current…
- Marc de Garidel, Abivax 🇫🇷 | Ulcerative Colitis, Inflammation | E46 · 54 min · Episode 46When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes. Philip meets Abivax CEO Marc de Garidel in Vienna…
- Laurent Levy, Nanobiotix 🇫🇷 | Nanoparticles, Radiotherapy | E45 · 50 min · Episode 45As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and…
- Gerrit Sitters, LUMICKS 🇳🇱 | CAR-T therapy, Single-Cell Analysis | E44 [Sponsored] · 1 h 24 min · Episode 44As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells…
